Safe Accelerated Venetoclax Escalation in CLL

Chronic Lymphocytic Leukemia Clinical Trial

— SAVE  

Official title:

SAVE (Safe Accelerated Venetoclax Escalation): A Phase Ib Study of Venetoclax Monotherapy With Accelerated Dose Ramp-up in Patients With CLL

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04843904
• Other study ID #: 20-415
• Status: Recruiting
• Phase: Phase 1
• Start date: April 14, 2021
• Est. completion date: June 2, 2030

Study information

• Verified date: June 2024
• Source: Dana-Farber Cancer Institute
• Contact: Celeste Carey, MS
• Phone: 877-DF-TRIAL
• Email: celeste_carey[@]dfci.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is trying to determine which patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as grouped by their risk for tumor lysis syndrome (TLS), are able to safely tolerate an accelerated, daily venetoclax dose ramp-up rather than the standard approved schedule (5-week dose ramp-up).

The name of the study drug involved in this study is:

• Venetoclax

The following drugs may also be included in some participants treatment regimen:

• Obinutuzumab

• Rituximab

Description:

This is an open label phase Ib study of an accelerated venetoclax ramp-up in patients with CLL/SLL in either the front-line or relapsed/refractory setting. This clinical trial is testing a new dosing schedule of a drug that is normally dosed in a different fashion. As such, venetoclax is considered an investigational drug when given in this new schedule. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has approved venetoclax as a treatment option for CLL or SLL but the approval is based on a different schedule.

Venetoclax is an oral drug inhibitor of BCL-2, a protein that regulates the death of cells in the body. It has been FDA approved with or without rituximab for the treatment of adult patients with CLL/SLL who have received at least one prior therapy, with obinutuzumab for frontline therapy of CLL/SLL, as well in combination with azacitabine, decitabine, or low-dose cytarabine for the treatment of adults with newly diagnosed acute myeloid leukemia (AML).

Venetoclax is typically started at a low dose and increased on a weekly basis, over 5 weeks, to the desired dose for patients with CLL/SLL.This study is trying to determine if patients can safely increase the venetoclax dose in the hospital on a daily basis, over 5 days rather than weekly, and which patients, grouped by their risk for TLS, with newly diagnosed or relapsed/refractory CLL/SLL, are able to safely tolerate this accelerated, daily venetoclax dose ramp-up.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

All participants will be actively followed for approximately 3 months. Following completion of the active study period, participants will be encouraged to return for a response evaluation. Following this, patients will enter a long-term follow up period where they will be observed for a maximum of 5 years.

It is expected that about 40 people will take part in this research study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 2, 2030
• Est. primary completion date: June 2, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma per IW-CLL 201814 requiring therapy based on at least one of the following criteria as listed below:

• Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin <11.0 g/L) and/or thrombocytopenia (platelets <100 x 109/L)

• Massive (=6 cm below the left costal margin), progressive, or symptomatic splenomegaly

• Massive nodes (at least 10 cm longest diameter), progressive, or symptomatic

• lymphadenopathy

• Progressive lymphocytosis with an increase of more than 50% over a 2-month period or LDT of <6 months. Lymphocyte doubling time may be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months.

• Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy

• Documented constitutional symptoms, defined as 1 or more of the following disease related symptoms or signs: unintentional weight loss >10% within 6 months prior to screening, significant fatigue (inability to work or perform usual activities), fevers >100.5° F or 38.0° C for 2 or more weeks prior to screening without evidence of infection, night sweats for more than 1 month prior to screening without evidence of infection

• Both previously untreated and relapsed or refractory patients will be eligible, including those who will be receiving venetoclax as monotherapy or in combination with anti-CD20 monoclonal antibody therapy

• Age greater or equal to 18 years

• ECOG performance status =2 (Karnofsky =60%, see Appendix A)

• Patients must meet the following hematologic criteria at screening, unless they have significant bone marrow involvement of CLL confirmed on biopsy:

• Absolute neutrophil count =1000 cells/mm3. Growth factor is allowed in order to achieve this

• Platelet count =25,000 cells/mm3 (25 x 109/L) independent of transfusion within 7 days of screening

• Adequate hepatic function defined as:

• Serum aspartate transaminase (AST) and alanine transaminase (ALT) = 3.0 x upper limit of normal (ULN), bilirubin =1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)

• Adequate renal function as defined as:

• Serum creatinine =1.5 times the ULN or creatinine clearance = 50 mL/min using a 24-hour urine collection

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal, barrier method or abstinence) prior to study entry and for the duration of study participation

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Treatment with venetoclax within the past 6 months

• Transformation of CLL to aggressive NHL (Richter's transformation or pro-lymphocytic leukemia)

• Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, surgery within 2 weeks of Cycle 1/Day 1 with the following exceptions:

• CD20 antibody therapy (i.e. rituximab or obinutuzumab) if it is being used as part of the venetoclax regimen (see inclusion criteria 3.1.2)

• For patients on targeted therapies, a washout of least five half lives is required

• Patients who experience clinical deterioration may start therapy after a shorter washout period with prior approval by the PI

• Corticosteroid therapy (prednisone or equivalent <=20 mg daily) is allowed

• Confirmed central nervous system involvement

• Allogeneic hematologic stem cell transplant within 6 months of starting study treatment or active graft vs. host disease (GVHD) requiring treatment or prophylaxis

• Active malignancy requiring therapy that would interact with venetoclax as per the discretion of the treating investigator

• Any active systemic infection requiring IV antibiotics or other uncontrolled, active infections

• Known history of human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)

• Major surgery within 4 weeks of first dose of study drug

• Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months of initial dosing on study

• Use of Coumadin for anticoagulation (other anticoagulants permitted)

• Lactating or pregnant

• Concurrent administration of medications or foods that are strong inhibitors or inducers of CYP3A . The concomitant use of drugs or foods that are strong or moderate inhibitors or inducers of CYP3A are not allowed beginning 1 week prior to the first dose of venetoclax.

• Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications

• Unable to swallow capsules or malabsorption syndrome, active disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction resulting in malabsorption or chronic diarrhea

• Active abuse of alcohol

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Small Lymphocytic Lymphoma

Intervention

Drug:
• Venetoclax
Tablet, taken by mouth
• Obinutuzumab
Given as an infusion into the vein (intravenous, IV).
• Rituximab
Given as an infusion into the vein (intravenous, IV).

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Highest risk TLS group that can safely tolerate the daily ramp up	Rates of laboratory and clinical TLS	3 months
Secondary	Objective response rate (ORR)	Evaluated using the 2018 iwCLL criteria for CLL	3 months
Secondary	Complete response (CR) rate	Evaluated using the 2018 iwCLL criteria for CLL	3 months
Secondary	Progression free survival (PFS)	Time to progression or death	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
Secondary	Overall survival (OS)	Death due to any cause	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
Secondary	Rate of undetectable minimal residual disease (uMRD)	Determined by flow cytometry and ClonoSeq	3 months